Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats.

Tonomura Y, Matsushima S, Kashiwagi E, Fujisawa K, Takagi S, Nishimura Y, Fukushima R, Torii M, Matsubara M.
Journal   Toxicology.
Species  
Analytes Measured   Troponin I cardiac , Troponin T cardiac , FABP3 , Myl3 , Troponin I fast-twitch
Matrix Tested   Plasma
Year   2012
Volume  
Page Numbers  
Application   Toxicology
Abstract
Cardiotoxicity and musculoskeletal toxicity can be life-threatening, and thus have strong impact on both the development and marketing of drugs. Because the conventional biomarkers such as aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) have low detection power, there has been increasing interest in developing biomarkers with higher detection power. The current study examined the usefulness of several promising biomarkers, cardiac and skeletal muscle troponins (cTnI, cTnT and sTnI), fatty acid binding protein 3 (FABP3) and myosin light chain 3 (MYL3), and compared the obtained data to AST, LDH and CK in rat models treated with various myotoxic and non-myotoxic compounds (isoproterenol, metaproterenol, doxorubicin, mitoxantrone, allylamine, cyclosporine A, cyclophosphamide, aminoglutethimide, acetaminophen, methapyrilene, allylalcohol and α-naphthylisothiocyanate). These promising biomarkers were found to be superior to the conventional biomarkers, as they had a specific and abundant distribution within the heart and/or skeletal muscles; exhibited a positive correlation between the amplitude of increases and the degree of pathological alterations; had higher diagnostic accuracy for detecting pathological alterations; and had the additive effect of improving the diagnostic accuracy of conventional biomarkers. However, these promising biomarkers have several drawbacks including a rapid clearance, the fact that they are affected by renal dysfunction, and different reactivity to the mode of action of individual myotoxicants. In conclusion, the promising biomarkers cTnI, cTnT, FABP3, MYL3, and sTnI demonstrated sensitivity and specificity for cardiac and skeletal myotoxicity that was superior to those of conventional biomarkers, while we should pay attention to the drawbacks of these biomarkers when used in toxicity studies.

View Publications

Related Products

R-PLEX Human FABP3/H-FABP Assay
FABP3/H-FABP | Human
Singleplex
R-PLEX Human Troponin T (cardiac) Assay
Troponin T (cardiac) | Human
Singleplex
R-PLEX Human Troponin I (cardiac) Assay
Troponin I (cardiac) | Human
Singleplex
R-PLEX Human Troponin I (cardiac) Antibody Set
Troponin I (cardiac) | Human
R-PLEX Human FABP3/H-FABP Antibody Set
FABP3/H-FABP | Human
R-PLEX Human Troponin T (cardiac) Antibody Set
Troponin T (cardiac) | Human
Muscle Injury Panel 3 Mouse Kit
FABP3/H-FABP, Myl3/CMLC1, Troponin I (cardiac), Troponin I (fast-twitch) | Mouse
Multiplex
Rat Cardiac Troponin ITC Complex Kit
Troponin I (cardiac), Troponin ITC Complex | Rat
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters